The document discusses the challenges of implementing a risk-based monitoring approach for clinical trials as outlined in FDA guidance. It notes that risk-based monitoring requires coordination across sponsors, clinical operations staff, clinical research associates, and clinical data managers. While the centralized data collection and monitoring enabled by clinical data management systems poses few technological challenges, ensuring smooth processes and workflows is key. The guidance acknowledges that changes to the clinical trial process are acceptable if they focus resources on important risks and improve efficiency.